Research programme: nanoliposomal docetaxel - TRACON
Latest Information Update: 11 Sep 2014
At a glance
- Originator TRACON Pharmaceuticals
- Mechanism of Action Mitosis inhibitors; Tubulin polymerisation inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 18 Jun 2007 Preclinical trials in Cancer in USA (unspecified route)